Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
FLNA
4826
Filana Therapeutics
FLNA
$45M
| $4.95K | ﹤0.01% |
2,734
-41,396
| -94% | -$73.7K |
2020 Q2
20 quarters
|
|
|
AIFC
4827
AI Financial Corp
AIFC
$70.4M
| $4.9K | ﹤0.01% |
+676
| New | +$4.75K |
2025 Q2
0 quarters
|
|
4828
Incannex Healthcare Limited Common Stock
IXHL
$40.3M
| $4.85K | ﹤0.01% |
750
| – | – |
2024 Q1
5 quarters
|
|
|
ZOCT
4829
Innovator Equity Defined Protection ETF - 1 Yr October
ZOCT
$106M
| $4.83K | ﹤0.01% |
186
-1,505
| -89% | -$38.3K |
2024 Q4
2 quarters
|
|
4830
Invesco Oil & Gas Services ETF
PXJ
$130M
| $4.76K | ﹤0.01% |
200
| – | – |
2023 Q4
6 quarters
|
|
4831
XTI Aerospace
XTIA
$29.6M
| $4.76K | ﹤0.01% |
+2,918
| New | +$5.25K |
2025 Q2
0 quarters
|
|
|
SNT
4832
Senstar Technologies
SNT
$35.9M
| $4.73K | ﹤0.01% |
1,000
| – | – |
2022 Q1
13 quarters
|
|
4833
Sutro Biopharma
STRO
$255M
| $4.72K | ﹤0.01% |
662
-10,967
| -94% | -$89.7K |
2018 Q4
26 quarters
|
|
|
CBIO
4834
Crescent Biopharma
CBIO
$532M
| $4.62K | ﹤0.01% |
286
+285
| +28,500% | +$6.03K |
2022 Q4
10 quarters
|
|
4835
Quantum Corp
QMCO
$1.36B
| $4.54K | ﹤0.01% |
455
-281
| -38% | -$3.11K |
2020 Q1
21 quarters
|
|
4836
Drilling Tools International
DTI
$80.8M
| $4.52K | ﹤0.01% |
1,586
-11,224
| -88% | -$27.9K |
2024 Q2
4 quarters
|
|
4837
GlucoTrack
GCTK
$1.23M
| $4.51K | ﹤0.01% |
+50
| New | +$6.59K |
2025 Q2
0 quarters
|
|
|
CVE.WS
4838
DELISTED
Cenovus Energy Inc Warrants
CVE.WS
| $4.5K | ﹤0.01% |
331
-25
| -7% | -$206 |
2022 Q1
13 quarters
|
|
4839
ALX Oncology
ALXO
$169M
| $4.39K | ﹤0.01% |
10,567
-37,462
| -78% | -$18.9K |
2022 Q1
13 quarters
|
|
4840
Cue Biopharma
CUE
$186M
| $4.11K | ﹤0.01% |
201
| – | – |
2019 Q1
25 quarters
|
|
4841
PepGen
PEPG
$158M
| $4.11K | ﹤0.01% |
3,704
-18,339
| -83% | -$25.9K |
2022 Q2
12 quarters
|
|
4842
Corbus Pharmaceuticals
CRBP
$119M
| $4.08K | ﹤0.01% |
591
-11,879
| -95% | -$86.3K |
2024 Q1
5 quarters
|
|
4843
AllianzIM U.S. Equity Buffer20 Apr ETF
APRW
$206M
| $4.04K | ﹤0.01% |
121
-3,474
| -97% | -$112K |
2025 Q1
1 quarter
|
|
4844
Dorchester Minerals
DMLP
$1.41B
| $3.93K | ﹤0.01% |
+141
| New | +$3.96K |
2025 Q2
0 quarters
|
|
4845
Achieve Life Sciences
ACHV
$746M
| $3.88K | ﹤0.01% |
1,716
-34,585
| -95% | -$98.5K |
2024 Q2
4 quarters
|
|
4846
Wheels Up
UP
$127M
| $3.87K | ﹤0.01% |
181
-4,689
| -96% | -$115K |
2023 Q4
6 quarters
|
|
4847
Telomir Pharmaceuticals
TELO
$81.2M
| $3.77K | ﹤0.01% |
3,017
-17,322
| -85% | -$40K |
2024 Q2
4 quarters
|
|
4848
iShares Asia/Pacific Dividend ETF
DVYA
$69.3M
| $3.77K | ﹤0.01% |
98
| – | – |
2017 Q4
30 quarters
|
|
|
GBIO
4849
DELISTED
Generation Bio
GBIO
| $3.67K | ﹤0.01% |
1,148
-4,967
| -81% | -$19.1K |
2022 Q1
13 quarters
|
|
|
LPAAU
4850
Launch One Acquisition Corp Unit
LPAAU
| $3.63K | ﹤0.01% |
344
| – | – |
2024 Q3
3 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.